Pivotal KEYNOTE-671 Trial Meets Dual Primary Endpoint of OS in Resectable Stage II, IIIA or IIIB NSCLC October 16, 2023
EXKIVITY® (mobocertinib) to be voluntary withdrawn from the U.S. for adult patients with EGFR Exon20 insertion+ mNSCLC whose disease has progressed on or after platinum-based chemotherapy October 11, 2023
Nektar Therapeutics and Cellular Biomedicine Group to Evaluate NKTR-255 + C-TIL051 in Advanced NSCLC October 3, 2023
Ph 3 MARIPOSA Study Meets Primary Endpoint of PFS for RYBREVANT (amivantamab-vmjw) + Lazertinib vs Osimertinib in EGFR-Mutated NSCLC October 3, 2023
Positive Clinical Data in Pancreatic Cancer and SCLC, including Single-Agent Activity from Onvansertib Monotherapy October 3, 2023
FDA grants Fast Track Designation to MYTX-011 for Patients with NSCLC with cMET Overexpression October 3, 2023
FAILED TRIALS: Ph 3 trials, LEAP-006 and LEAP-008, of KEYTRUDA + LENVIMA in patients with certain types of mNSCLC did not meet primary endpoints of OS & PFS September 26, 2023
Perioperative Regimen of Neoadjuvant Opdivo and Chemotherapy Followed by Adjuvant Opdivo Significantly Improves EFS in Patients with Resectable NSCLC September 26, 2023
Ph 2 EVOKE-02 Study Of Trodelvy + KEYTRUDA Demonstrates Promising Clinical Activity In 1L mNSCLC September 19, 2023
Datopotamab deruxtecan + Imfinzi showed promising clinical activity in 1L advanced NSCLC in TROPION-Lung04 Ph 1b trial September 19, 2023
Enhertu demonstrated strong and durable tumor responses in previously treated HER2-mutant advanced lung cancer in DESTINY-Lung02 Ph 2 trial September 19, 2023
New Lumakras® (Sotorasib) Plus Chemotherapy Data In First-Line KRAS G12C NSCLC announced September 19, 2023
Patritumab Deruxtecan Demonstrated Clinically Meaningful and Durable Responses in Patients with EGFR-Mutated mNSCLC in HERTHENA-Lung01 Ph 2 Trial September 19, 2023
Enhertu recommended for approval in the EU by CHMP for patients with HER2-mutant advanced NSCLC September 19, 2023
Positive EU CHMP Opinion for KEYTRUDA as Adjuvant Treatment for Adults with NSCLC at High Risk of Recurrence Following Complete Resection and Platinum-Based Chemo September 19, 2023
Ph 3 MARIPOSA-2 Study Meets Dual Primary Endpoint Resulting in PFS Improvement with RYBREVANT + Chemo +/- Lazertinib vs chemo Alone in Patients with EGFR-Mutated NSCLC after Disease Progression on Osimertinib September 13, 2023
Datopotamab deruxtecan plus Imfinzi showed promising clinical activity in the 1L advanced NSCLC setting in TROPION-Lung04 Phase Ib trial September 13, 2023
Tagrisso plus chemotherapy extended mPFS by nearly 9 months in EGFR-mutated advanced lung cancer in FLAURA2 Phase III trial September 13, 2023
Phase III ALINA study of Alecensa® (alectinib), compared with platinum-based chemotherapy, met its primary endpoint of disease-free survival (DFS) September 6, 2023
Tecentriq subcutaneous (SC) is approved in Great Britain for all indications of IV Tecentriq, offering a faster, more convenient option to receive treatment September 6, 2023
